Alcide Corporation Announces SANOVA Approved for Post-Chill Use on Poultry.

Business Editors, Health/Medical Writers

BIOWIRE2K

REDMOND, Wash.--(BW HealthWire)--May 9, 2001

Alcide Corporation (Nasdaq:ALCD) today announced that the U.S. Food and Drug Administration (FDA) and the U.S. Department of Agriculture (USDA) have approved the Company's SANOVA(R) antimicrobial for use on poultry, poultry parts and organs post-chill.

In a typical automated poultry processing facility, carcasses are immersed in a hydro-chiller prior to cut up, deboning or other further processing and packaging. SANOVA has been approved since 1998 for pre-chill use in poultry processing plants to substantially reduce human health threats caused by microbiological pathogens such as E. coli, Salmonella and Campylobacter. The product is presently used in 28 processing plants for antimicrobial treatment of roughly 5 billion pounds of poultry on an annual basis.

This latest approval for SANOVA use post-chill provides the poultry industry with a much needed safe and effective method to address potential cross contamination which may occur in the hydro-chilling process, or new contamination in the cut-up, grinding or further processing of poultry products. Most food safety experts believe that a "multi-hurdle" approach to pathogen reduction is necessary for effective control.

SANOVA is now the most broadly approved antimicrobial for use on food. Previous approvals include use on red meat pre-chill, red meat post-chill, intact fruits and vegetables in processing plants and poultry pre-chill.

Chairman and Chief Executive Officer, Joseph A. Sasenick, noted that, "The expanding regulatory approvals for use of SANOVA are testimony to the safety and performance of Alcide's technology. Several poultry customers have expressed an interest in using SANOVA on whole carcasses, parts and organs post-chill. Our Food Safety group will begin the commercialization process this summer."

Alcide Corporation develops and markets unique biocidal products based on its patented technology. The Company sells anti-infective products to the animal health market, disinfecting products to the medical industries, and SANOVA(R) for controlling food borne pathogens.

This report includes forward looking statements which involve risk and uncertainty including, without limitation, risk of dependence on third party suppliers, market acceptance of and demand for the Company's products, distribution capabilities and development of technology and regulatory approval thereof.